NextCure has entered a strategic partnership with Simcere Zaiming, to develop SIM0505, a new ADC targeting CDH6 for treating ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to buy the postpartum depression pill developer.

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Ethris has entered a strategic partnership with Thermo Fisher Scientific for providing completely integrated mRNA solution.

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Lynozyfic’s global sales are projected to reach $707 million by 2031.

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

The future of US immunisation is up in the air as outspoken critics of vaccines populate an integral recommendation committee ...

GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will change the treatment paradigm.

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).